AboutOpenBackground: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi +2 more
openalex +4 more sources
Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis [PDF]
Arthritis Research & TherapyBackground We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O).
Marina G. Birck +12 more
doaj +2 more sources
The paradigm of introduction of biosimilars of original medicines in the world modern pharmaceutical market [PDF]
AIP Conference Proceedings, 2021 Maya F. Krichevskaya
openalex +2 more sources
Impact of biosimilar medicinal products in the EU pharmaceutical market [PDF]
Clinical Therapeutics, 2015 Aleksandra Grozdanova +5 more
openalex +2 more sources
From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry [PDF]
Technological Forecasting and Social Change, 2018 Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology ...
Dinar Kale
openalex +2 more sources
P & T : a peer-reviewed journal for formulary management, 2014 Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
Stephen Barlas
openalex +3 more sources
Pharmaceutics, 2023 Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab.
Natalia Riva +10 more
doaj +1 more source
Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models [PDF]
Acta Cirúrgica Brasileira, 2018 Purpose: To evaluate the toxicity of Erbitux as well as its biosimilar APZ001 antibody (APZ001) in pre-clinical animal models including mice, rabbits and cynomolgus monkeys.
Xiaofei Wang +7 more
doaj +2 more sources
Pharmaceuticals, 2020 Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region.
Evelien Moorkens +8 more
doaj +1 more source
EE339 The Biosimilars’ Economic Evaluation in Contrast With Judicializations’ Economic Impacts of the Pharmaceutical Assistance in Brazil [PDF]
Value in HealthErika Tanaka +3 more
openalex +2 more sources